Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF) said its Traumakine drug has shown early promise as a potential therapeutic for emergency and trauma patients, especially when given early on.
The company said primates were treated intravenously with interferon beta-1a formulation at the time of major inflammation due to ischemia (where blood flow and oxygen are restricted to a part of the body).
The results of the study showed lower levels of muscle and liver damage markers, indicating total body protection, the company noted. In fact, there was full restoration of limb function seen with no evidence of muscle atrophy or degeneration.
"This promising evidence supports further trials with Traumakine to understand its potential military application and in human surgical procedures where ischemic organs are often seen,” said Vija Gorantla, Professor of Surgery at Wake Forest Institute for Regenerative Medicine in a statement.
The study, codenamed SPARES, involved investigators from Wake Forest, Duquesne University and the 59th Medical Wing of the US Air Force. Funding came from America’s Department of Defense.
Data from the study will be presented at the Military Health System Research Symposium, which is currently underway in Orlando, Florida.